Meeting Coverage
ASCO GI
American Society of Clinical Oncology
The Gastrointestinal Cancers Symposium
ORLANDO -- Patients with progressive pancreatic neuroendocrine tumors lived twice as long without progression when treated with sunitinib (Sutent) compared with placebo, data from a French clinical trial showed.
Latest ASCO GI Meeting Coverage
ORLANDO -- The addition of Avastin (bevacizumab) to Gemzar (gemcitabine) did not improve survival of advanced pancreatic cancer in a randomized trial, researchers here reported.
January 22, 2007
Latest Oncology/Hematology Meeting Coverage
-
SNO: Society for NeuroOncology
November 2024
-
ASTRO: American Society for Radiation Oncology
September 2024
-
ESMO: European Society for Medical Oncology
September 2024
-
ASCO: American Society of Clinical Oncology
May 2024